FG-001 Computational Set FireGate Biotech
Description
This dataset accompanies the structural modeling report “Structural Modeling Update: Triplet-Axis Assembly” (FireGate Biotech Inc.). The work evaluates whether CCR5 antagonism, PD-L1 modulation, and PD-L1-directed antibody activity could plausibly operate through a single three-body structural complex. Curated Protein Data Bank structures for CCR5 (4MBS), PD-L1 (8GAD), and a PD-L1-targeted nanobody used as an antibody proxy (5DXW) were opened and examined in UCSF ChimeraX (daily build, 2025-10-13, macOS). Models were aligned, colored, and inspected for steric compatibility, using an approximate clash threshold of 4 Å. In all explored orientations, no sterically permissive triplet geometry was identified, suggesting that synergy across these axes is more likely mediated by indirect regulatory and signaling interactions rather than direct CCR5–PD-L1–antibody co-binding. The figures and any included ChimeraX sessions are intended to document this conceptual geometric assessment. They are not clinical data and do not represent validated therapeutic outcomes.
Files
Steps to reproduce
Structural visualization was performed in UCSF ChimeraX (daily build, 2025-10-13, macOS). To reproduce the assessment, download PDB entries 4MBS, 8GAD, and 5DXW, open them in ChimeraX, orient CCR5 and PD-L1 to compare extracellular exposure, then introduce 5DXW as an antibody proxy. Manually explore placements of the nanobody relative to both targets and inspect for steric clashes using a ∼4 Å threshold. No automated docking was used; this is a qualitative geometric analysis.